Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1981 in moderate to severe COPD
NL-OMON32403Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of timapiprant in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoints: Aggregate pathology score, Cell counts of BAL fluid and 1 more. Planned start Sep 2008; status: not yet recruiting.
02
Drugs
timapiprant
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON32403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32403.